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optimizing central venous pressure
(CVP) and oxygen saturation (ScvO2)
as hypothesized by Angus et al.
EGDT was a prospective randomized trial where resuscitation was
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Dear Editor,
A review and meta-analysis published
by Angus and colleagues [1] concludes: ‘‘EGDT (early goal-directed
therapy) does not decrease mortality
but increases costs’’ and suggests:
‘‘EGDT should not be part of the
Surviving Sepsis Campaign (SSC)
guidelines’’. This conclusion, while
interesting, is incorrect for numerous
methodological reasons. EGDT was
the result of a series of studies over
two decades identifying poor care,
early sepsis mortality, early identification (SIRS), risk stratification
(lactate), cultures and antimicrobials,
identifying cryptic shock and early
hemodynamic optimization to treat
global tissue hypoxia in the emergency department (ED) [2]. While
considered standard care in the ICU
setting, these principles were applied
to the most proximal part of hospitalization as ischemic stroke, acute
myocardial infarction, or trauma was
treated. EGDT is more than

conducted in the ED and blinded to
the ICU team. Angus et al. incorrectly
labels the EGDT unblinded. The trial
Trilogy, completed a decade later,
was unblinded and included as
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Fig. 1 Relative risk correlation with control group mortality. In studies with
higher mortality treatment with EGDT leads to a more pronounced reduction in the
relative risk of mortality than studies with lower mortality. *Lactate clearance formula:
[(LactateInitial - LactateRepeat)/LactateInitial) 9 100 %
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standard care all elements of EGDT
except CVP and ScvO2 in all groups.
Before and during the conduction of
the Trilogy numerous publications
incorporating EGDT (SSC guidelines) have shown a consistent
mortality reduction over the last
decade. It is no surprise that mortality
was diminished and little difference
exists between groups in the Trilogy
of trials.
An acceptable alternative to randomized controlled trials (RCTs) are
prospective observational trials
(POTs). POTs importantly reflect the
reality of implementation and the
bedside clinical scientist’s contributions to the literature rather than large
institutional funded trials. In POTs
using EGDT comprising over 62,260
patients, a mortality reduction of
13.3 % [from 40 ± 11 to
26.7 ± 11 % (P \ 0.001)] has been
shown, which compares to the original EGDT trial of 46–30 %. Multiple
investigators, including the Cochrane
Collaborative, have shown that there
is little evidence that estimates of
treatment effects in POTs reported
after 1984 are either consistently larger than or qualitatively different
from those obtained in RCTs [3, 4].
Re-examination of the RCTs analyzed by Angus reveals a significant
benefit in patients of greater illness
severity (Fig. 1). The focus of the
analysis should reflect whether invasive monitoring is necessary to realize
the mortality benefits of EGDT in
various hemodynamic subgroups.
Limitations of these studies (heterogeneity in enrolled patients, pediatric
and adult populations, unblinded care,

influences of existing sepsis protocols, and central venous
catheterization rates greater than
50 % in all groups) need to be
methodically examined. These and
other systematic biases need to be
addressed [5] along with assessment
of validity, informativeness, and limitations of the review process. The
conclusion should be a general interpretation of the results in the context
of other evidence, and implications
for future research as described by the
PRISMA statement (Supplement 1).
The analysis should be a celebration of an all-time low in sepsis
mortality and the success of SSC with
EGDT. The retreat to embrace
another repeat negative study with
serious systematic biases is not in the
best interest of patient care. EGDT is
not a noun which is to be liked or
disliked; it is a verb or a series of
actions. These actions have been
shown to be successful and are
amendable to change not removal.
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